Browse Wiki & Semantic Web

Jump to: navigation, search
Http://dbpedia.org/resource/Chengdu Kanghong Pharmaceutical Group
  This page has no properties.
hide properties that link here 
  No properties link to this page.
 
http://dbpedia.org/resource/Chengdu_Kanghong_Pharmaceutical_Group
http://dbpedia.org/ontology/abstract Chengdu Kanghong Pharmaceutical Group Co.,Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, central nervous, digestive and endocrine systems. The company is listed on the Shenzhen stock exchange with a market capitalization at around $6 billion. As of May 2021, the company had 18 drugs on the market including Lumitin (conbercept). Additional products include Songling xuemaikang capsules, Keluoxin capsules, Xinluona (Mosapride Citrate), Bolexin (Venlafaxine hydrochloride capsules) and Bosiqing (Aripiprazole tablets), Yitaning (Dexzopiclone tablets), Shugan Jieyu (capsules), Danshu (capsules), and Yiqing (capsules). Kanghong also currently has 13 subsidiaries in China, Israel, and the United States.s in China, Israel, and the United States.
http://dbpedia.org/ontology/wikiPageID 67745157
http://dbpedia.org/ontology/wikiPageLength 5420
http://dbpedia.org/ontology/wikiPageRevisionID 1098097403
http://dbpedia.org/ontology/wikiPageWikiLink http://dbpedia.org/resource/Human_digestive_system + , http://dbpedia.org/resource/Ophthalmology + , http://dbpedia.org/resource/Sichuan%2C_China + , http://dbpedia.org/resource/Age-related_Macular_Degeneration + , http://dbpedia.org/resource/Glioma + , http://dbpedia.org/resource/Type_2_diabetes + , http://dbpedia.org/resource/Diabetic_Macular_Edema + , http://dbpedia.org/resource/Central_nervous_system + , http://dbpedia.org/resource/Phase_III_clinical_trials + , http://dbpedia.org/resource/Research_and_development + , http://dbpedia.org/resource/U.S._FDA + , http://dbpedia.org/resource/COVID-19_pandemic + , http://dbpedia.org/resource/Endocrine_system + , http://dbpedia.org/resource/Shenzhen_Stock_Exchange + , http://dbpedia.org/resource/Conbercept + , http://dbpedia.org/resource/Category:Companies_of_China +
http://dbpedia.org/property/wikiPageUsesTemplate http://dbpedia.org/resource/Template:Reflist + , http://dbpedia.org/resource/Template:Fanpov + , http://dbpedia.org/resource/Template:Short_description + , http://dbpedia.org/resource/Template:COI + , http://dbpedia.org/resource/Template:Multiple_issues +
http://purl.org/dc/terms/subject http://dbpedia.org/resource/Category:Companies_of_China +
http://www.w3.org/ns/prov#wasDerivedFrom http://en.wikipedia.org/wiki/Chengdu_Kanghong_Pharmaceutical_Group?oldid=1098097403&ns=0 +
http://xmlns.com/foaf/0.1/isPrimaryTopicOf http://en.wikipedia.org/wiki/Chengdu_Kanghong_Pharmaceutical_Group +
owl:sameAs http://dbpedia.org/resource/Chengdu_Kanghong_Pharmaceutical_Group + , http://www.wikidata.org/entity/Q107132495 + , https://global.dbpedia.org/id/Fv3st +
rdfs:comment Chengdu Kanghong Pharmaceutical Group Co.,Chengdu Kanghong Pharmaceutical Group Co., Ltd. is a publicly traded pharmaceutical company based in the province of Sichuan, China. It was founded in 1996 and researches, develops, manufactures, and distributes medicines for ophthalmic, central nervous, digestive and endocrine systems. The company is listed on the Shenzhen stock exchange with a market capitalization at around $6 billion.arket capitalization at around $6 billion.
rdfs:label Chengdu Kanghong Pharmaceutical Group
hide properties that link here 
http://dbpedia.org/resource/Conbercept + http://dbpedia.org/ontology/wikiPageWikiLink
http://en.wikipedia.org/wiki/Chengdu_Kanghong_Pharmaceutical_Group + http://xmlns.com/foaf/0.1/primaryTopic
 

 

Enter the name of the page to start semantic browsing from.